CO5261534A1 - Uso de inhibidores de secrecion de apoliproteinas b y/o de proteina de transferencia de trigliceridos microsomales - Google Patents

Uso de inhibidores de secrecion de apoliproteinas b y/o de proteina de transferencia de trigliceridos microsomales

Info

Publication number
CO5261534A1
CO5261534A1 CO00085765A CO00085765A CO5261534A1 CO 5261534 A1 CO5261534 A1 CO 5261534A1 CO 00085765 A CO00085765 A CO 00085765A CO 00085765 A CO00085765 A CO 00085765A CO 5261534 A1 CO5261534 A1 CO 5261534A1
Authority
CO
Colombia
Prior art keywords
microsomal
animal
secretion
apolipoprotein
inhibitor
Prior art date
Application number
CO00085765A
Other languages
English (en)
Inventor
Charles Edward Chendler
Mary Anne Hickman
Marie Lundy Kristin
Bradley Paul Morgan
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of CO5261534A1 publication Critical patent/CO5261534A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

El invento proporciona métodos útiles en reducir la absorción grasa intestinal en un animal, preferiblemente un mamífero incluyendo un sujeto humano o un animal de compañía, los cuales comprenden administrar a un animal en necesidad de tal reducción, una cantidad de un inhibidor de la secreción de la apolipoproteína Blproteína de transferencia de triglicéricos microsomales, preferiblemente en combinación con un agente anti-obesidad. El invento además proporciona composiciones farmacéuticas que comprenden cantidades de un inhibidor de la secreción de la apolipoproteína Blproteína de transferencia de triglicéricos microsomales y un agente anti-obesidad, y métodos de utilizar tales composiciones en la reducción de la absorción intestinal de grasa en un animal, preferiblemente un mamífero incluyendo un sujeto humano o un animal de compañía, en necesidad de tal reducción. El invento además proporciona un kit el cual comprende una cantidad de un inhibidor de la secreción de la apolipoproteína Blproteína de transferencia de triglicéricos microsomales y un portador, vehículo o diluyente farmacéuticamente aceptable en una primera forma de dosificación unitaria; una cantidad de un agente anti-obesidad y un portador, vehículo o diluyente farmacéuticamente aceptable en una segunda forma de dosificación unitaria; yun recipiente.<EMI FILE="00085765_1" ID="1" IMF=JPEG >
CO00085765A 1999-11-10 2000-11-10 Uso de inhibidores de secrecion de apoliproteinas b y/o de proteina de transferencia de trigliceridos microsomales CO5261534A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16454799P 1999-11-10 1999-11-10

Publications (1)

Publication Number Publication Date
CO5261534A1 true CO5261534A1 (es) 2003-03-31

Family

ID=22595001

Family Applications (1)

Application Number Title Priority Date Filing Date
CO00085765A CO5261534A1 (es) 1999-11-10 2000-11-10 Uso de inhibidores de secrecion de apoliproteinas b y/o de proteina de transferencia de trigliceridos microsomales

Country Status (11)

Country Link
EP (1) EP1099439A3 (es)
JP (1) JP2001172180A (es)
KR (1) KR20010051558A (es)
AU (1) AU6968700A (es)
CA (1) CA2324800A1 (es)
CO (1) CO5261534A1 (es)
HU (1) HUP0004461A3 (es)
IL (1) IL139448A0 (es)
NZ (1) NZ508059A (es)
PE (1) PE20010705A1 (es)
ZA (1) ZA200006419B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA200502496B (en) 2002-02-28 2005-10-12 Japan Tobacco Inc Ester compound and medicinal use thereof.
US6825209B2 (en) 2002-04-15 2004-11-30 Research Triangle Institute Compounds having unique CB1 receptor binding selectivity and methods for their production and use
EP1669345A4 (en) 2003-08-29 2008-02-20 Japan Tobacco Inc ESTER DERIVATIVE AND MEDICAL USE THEREOF
US20060084636A1 (en) * 2004-10-18 2006-04-20 Maria Alemany Methods of using fatty-acid esters of estrogens and serotonin reuptake inhibiting compounds for reducing the body weight of a mammal and compositions containing the same
US8101774B2 (en) 2004-10-18 2012-01-24 Japan Tobacco Inc. Ester derivatives and medicinal use thereof
WO2006046623A1 (ja) * 2004-10-25 2006-05-04 Japan Tobacco Inc. 溶解性及び安定性の改善された固形製剤及びその製造方法
ZA200704246B (en) * 2004-10-25 2009-09-30 Japan Tobacco Inc Solid medicinal preparation improved in solubility and stability and process for producing the same
US9035059B2 (en) * 2011-03-14 2015-05-19 Taisho Pharmaceutical Co., Ltd. Nitrogen-containing condensed heterocyclic compound

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2091102C (en) * 1992-03-06 2009-05-26 John R. Ii Wetterau Microsomal triglyceride transfer protein
US5474993A (en) * 1994-06-14 1995-12-12 Sterling Winthrop, Inc. Lactam inhibitors of cholesterol esterase
EP0832069B1 (en) * 1995-06-07 2003-03-05 Pfizer Inc. BIPHENYL-2-CARBOXYLIC ACID-TETRAHYDRO-ISOQUINOLIN-6-YL AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND/OR APOLIPOPROTEIN B (Apo B) SECRETION
EP0902785B1 (en) * 1996-04-30 2002-09-04 Pfizer Inc. Processes and intermediates for preparing 4'-trifluoromethylbiphenyl-2-carboxylic acid 2-(2h- 1,2,4]triazol-3-ylmethyl)-1,2,3,4-tetrahydro-isoquinolin-6-yl]-amide
SK65499A3 (en) * 1996-11-27 2001-05-10 Pfizer Apo b-secretion/mtp inhibitory amides
US5968950A (en) * 1997-06-23 1999-10-19 Pfizer Inc Apo B-secretion/MTP inhibitor hydrochloride salt
IL133201A0 (en) * 1998-12-04 2001-03-19 Pfizer Prod Inc Lowering blood levels of lipoproten (a)

Also Published As

Publication number Publication date
JP2001172180A (ja) 2001-06-26
CA2324800A1 (en) 2001-05-10
EP1099439A3 (en) 2003-03-26
IL139448A0 (en) 2001-11-25
NZ508059A (en) 2002-11-26
HU0004461D0 (es) 2001-01-29
KR20010051558A (ko) 2001-06-25
ZA200006419B (en) 2002-05-08
HUP0004461A3 (en) 2004-04-28
EP1099439A2 (en) 2001-05-16
AU6968700A (en) 2001-05-17
HUP0004461A2 (hu) 2001-10-28
PE20010705A1 (es) 2001-07-11

Similar Documents

Publication Publication Date Title
ES2528384T3 (es) Métodos de utilización de inhibidores del receptor de adenosina para potenciar la respuesta inmunitaria y la inflamación
AR034900A1 (es) Uso de una cantidad eficaz de un inhibidor de pde4 y un agente anticolinergico, bien en forma combinada sola o por separado, composiciones farmaceuticas que los comprenden, metodo para prepararlas, y uso de una composicion que comprende una cantidad eficaz de un inhibidor de pde4, una cantidad efica
CO5261582A1 (es) Composiciones de valdecoxib
AR037255A1 (es) Composiciones farmaceuticas que contienen oxibutinina
BR0107869A (pt) Composições farmacêuticas eletrogiradas
AR033548A1 (es) Composicion farmaceutica que comprende un inhibidor de lipasa, un procedimiento para su preparacion, equipo transportable a modo de &#39;&#39;kit&#39;&#39;, el uso de dicha composicion en la fabricacion de medicamentos, un inhibidor de lipasa y un secuestrante de acidos biliares
AR090677A2 (es) Preparacion farmaceutica que contiene oxicodona y naloxona
CO4970819A1 (es) Tratamiento de disfuncion sexual femenina en una hembra humana
MX2009004203A (es) Combinaciones de paracetamol/ibuprofeno y metodo para su uso.
AR053541A1 (es) Combinacion de xolair con agente inmunosupresor
CL2008003938A1 (es) Uso de escitalopram o de una sal farmaceuticamente aceptable del mismo para preparar un medicamento util en el tratamiento del desorden de estres postraumatico (divisional sol. 1799-00).
PL1781277T3 (pl) Kompozycja łączona zawierająca ibuprofen i paracetamol
EE05423B1 (et) IL-18 inhibiitori kasutamine maksakahjustuse ja muude haiguste raviks v?i ennetamiseks sobiva ravimi valmistamiseks, vektori ja raku kasutamine inhibiitori produtseerimisel ning IL-18 inhibiitorit sisaldav farmatseutiline kompositsioon
ECSP045025A (es) Combinación de opioides seleccionados con antagonistas muscarnicos para el tratamiento de la incontinencia urinaria
PE68899A1 (es) Composicion que contiene paracetamol
CO5261534A1 (es) Uso de inhibidores de secrecion de apoliproteinas b y/o de proteina de transferencia de trigliceridos microsomales
BR0306732A (pt) Tratamentos em combinação para doença alérgica compreendendo a administração de um anticorpo anti-ige e composto antialérgico
BR0206819A (pt) Uso de inibidores de il-18 para o tratamento e/ou para a prevenção de doença cardìaca
AR014640A1 (es) UNA COMPOSICíoN FARMACÉUTICA INHIBIDORA DE LA DISEMINACIoN METASTÁSICA DURANTE LA CIRUGíA DE UN TUMOR CANCEROSO, UN PROCEDIMENTO DE PREPARACIoN Y UN KIT PARA UNA FORMULACIoN INYECTABLE.
AR036321A1 (es) Metodo y formulacion farmaceutica para el tratamiento de la discinesia de aparicion tardia.
AR039162A1 (es) Formulaciones de venlafaxina de liberacion extendida
CO5271688A1 (es) Uso de inhibidor de secrecion de apoliproteinas b y/o de proteina de transferencia de trigliceridos microsmales
AR043016A2 (es) Un compuesto antimigranico eletriptan y composicion farmaceutica que lo contiene
AR012638A1 (es) Uso de pregnan-3-ol-20-onas para la manufactura de un medicamento util para proveer una terapia progestacional
NL1022442C2 (nl) Toepassing van lipide ter verbetring van de opname van nutrienten en (farmaceutisch) actieve stoffen.

Legal Events

Date Code Title Description
FC Application refused